TY  - JOUR
T1  - From Platform Readiness to Patient Readiness through a Decision Architecture for Next-Generation Pharmaceutical Translation under Scientific Uncertainty
A1  - James Walker
A1  - Olivia Harris
A1  - George Wilson
JF  - International Journal of Pharmaceutical Research and Allied Sciences
JO  - Int J Pharm Res Allied Sci
SN  - 2277-3657
Y1  - 2026
VL  - 15
IS  - 2
DO  - 10.51847/5GTArIIafD
SP  - 20
EP  - 29
N2  - Next-generation pharmaceutical platforms can generate compounds, models, assays, manufacturing processes, and human-relevant experimental evidence with increasing speed and technical sophistication. Yet platform performance is frequently interpreted as evidence of translational maturity before product-specific quality, biological consequence, pharmacological behaviour, clinical utility, or implementation feasibility has been established. This article develops an original Translational Decision Architecture for distinguishing platform readiness from patient readiness under scientific uncertainty. The proposed architecture treats translation as a sequence of connected but non-substitutable evidence domains: platform performance and reproducibility; product-specific manufacturability and quality; biological consequence and mechanism validation; pharmacological and safety translation; clinical utility and usability; and implementation readiness. Advancement between domains is governed by conditional evidence-transition gates rather than by a single maturity score or linear development ladder. Patient readiness is defined not as an approved status but as a context-specific decision condition requiring adequate evidence across all domains relevant to the proposed use. The architecture further introduces evidence warrants, explicit context-of-use statements, non-compensatory constraints, uncertainty-weighted decision gates, readiness regression, stopping rules, and an evidence-renewal function. Clinical utility, usability, and implementation are treated as constitutive translational requirements rather than downstream operational considerations. Validation would require retrospective and prospective testing across computational, experimental, manufacturing, pharmacological, clinical, and implementation settings. The architecture does not establish predictive accuracy, therapeutic effectiveness, regulatory acceptability, or universal applicability. Its principal contribution is a falsifiable conceptual structure for preventing technical achievement from being mistaken for patient-relevant pharmaceutical readiness. 
UR  - https://ijpras.com/article/from-platform-readiness-to-patient-readiness-through-a-decision-architecture-for-next-generation-pha-ixmtaixkr6rgqyx
ER  -